BioPharma Dive June 8, 2023
Jonathan Gardner

Moderna presented new data at ASCO for its melanoma shot, highlighting progress with a personalized approach that’s also being pursued by BioNTech and Gritstone.

The development of therapeutic vaccines for cancer has met repeated disappointment over the years, as treatments aimed at cancers of the brain, lung and kidney have failed in clinical testing.

But now, developers like Moderna, BioNTech and Gritstone Bio are pushing forward with personalized, messenger RNA vaccines that have revitalized hopes these treatments could boost human immunity to keep cancer at bay.

The American Society for Clinical Oncology’s annual meeting, held this week in Chicago, was the latest forum for Moderna and partner Merck & Co. to disclose data for a cancer shot they’re developing, called...

Today's Sponsors

Upfront Healthcare

Today's Sponsor


Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
Big Food vs. Big Pharma: Companies bet on snacking just as weight loss drugs boom
Preventative Drug Lists Led to More Affordable Asthma Medication
Lawsuits To Block Medicare Drug Price Negotiations Are Very Unpopular Among Voters
Avalyn’s New Twist on Older Lung Disease Drugs Attracts $175M for Clinical Trials
GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next?

Share This Article